Thomas J. Raife
Department of Pathology
University of Iowa Carver College of Medicine
Iowa City
IA 52240
USA
Name/email consistency: high
- Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Raife, T.J., Cao, W., Atkinson, B.S., Bedell, B., Montgomery, R.R., Lentz, S.R., Johnson, G.F., Zheng, X.L. Blood (2009)
- The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma. Raife, T.J., Friedman, K.D., Dwyre, D.M. Transfusion (2006)
- The changing paradigm of thrombotic thrombocytopenic purpura. Raife, T.J. Semin. Thromb. Hemost. (2005)
- Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Raife, T., Atkinson, B., Montgomery, R., Vesely, S., Friedman, K. Transfusion (2004)
- Lepirudin prevents lethal effects of Shiga toxin in a canine model. Raife, T., Friedman, K.D., Fenwick, B. Thromb. Haemost. (2004)
- Pathogenesis of thrombotic thrombocytopenic purpura. Raife, T.J. Curr. Hematol. Rep. (2003)
- Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Raife, T.J., Lentz, S.R., Atkinson, B.S., Vesely, S.K., Hessner, M.J. Blood (2002)
- Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects. Raife, T.J., Lager, D.J. Mayo Clin. Proc. (2002)
- New aspects in the pathogenesis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Raife, T., Montgomery, R. Rev. Clin. Exp. Hematol (2001)









